Bortezomib in Type I Cryoglobulinemic Vasculitis: Are We Acting Too Late?

E-resources

PDF

Peer reviewed Open access

Bortezomib in Type I Cryoglobulinemic Vasculitis: Are We Acting Too Late?

Ramirez, Giuseppe A.; Campochiaro, Corrado; Salmaggi, Chiara; Pagliula, Gaia; D'Aliberti, Teresa; Marcatti, Magda; Tresoldi, Moreno; Praderio, Luisa

Internal Medicine, 01/2015, Volume: 54, Issue: 9

Journal Article

Type II and type III cryoglobulinemic vasculitis (CV) are characterized by a deranged immune function due to concomitant chronic infections or rheumatic disorders. Conversely, type I CV is caused by plasma cell dyscrasia. Bortezomib is a proteasome inhibitor that is largely employed as a first-line treatment for multiple myeloma. The use of bortezomib in cases of monoclonal gammopathy of undetermined significance (MGUS)-related refractory type I CV has been reported in only four patients. In the current report, we discuss the efficacy of bortezomib treatment in a patient with type I CV, with a focus on the suitability and early application of this drug.

Keep searching

Author

Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.

Year	Impact factor		Edition		Category		Classification
Year	JCR	SNIP	JCR	SNIP	JCR	SNIP	JCR	SNIP

Links to authors' personal bibliographies	Links to information on researchers in the SICRIS system

Source: Personal bibliographies and: SICRIS

Upload image

Shelf entry

Adding material to shelf was successful.

Adding material to shelf failed.

It was not necessary to add the material to the shelf.

Permalink

E-mail

Impact factor

Select the library membership card:

DRS, in which the journal is indexed

Citations

Theme